Christopher H. van Dyck
#133,737
Most Influential Person Now
Christopher H. van Dyck's AcademicInfluence.com Rankings
Christopher H. van Dyckbiology Degrees
Biology
#11468
World Rank
#14866
Historical Rank
#2562
USA Rank
Neuroscience
#2629
World Rank
#2699
Historical Rank
#325
USA Rank
Christopher H. van Dyckphilosophy Degrees
Philosophy
#12612
World Rank
#17563
Historical Rank
#2482
USA Rank
Logic
#9508
World Rank
#12065
Historical Rank
#1703
USA Rank
Download Badge
Biology Philosophy
Christopher H. van Dyck's Degrees
- Doctorate Medicine Columbia University
Why Is Christopher H. van Dyck Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christopher H. van Dyck , is the Founder and Director of the Alzheimer’s Disease Research Unit at Yale University School of Medicine, where he is Professor of Psychiatry, Neurology and Neuroscience. His research uses brain imaging to learn about the progression of pathology in Alzheimer's disease, and to test potential new treatments for this disease.
Christopher H. van Dyck's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial (2000) (905)
- Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography (1998) (512)
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease (2012) (248)
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise (2018) (232)
- Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment (2005) (212)
- Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo (2010) (207)
- The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans (2001) (195)
- Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial (2002) (138)
- The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task (2000) (132)
- Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease (2006) (121)
- Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors (2004) (77)
- Hippocampal volume is associated with memory but not nonmemory cognitive performance in patients with mild cognitive impairment (2007) (64)
- Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT (2009) (64)
- The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys (1997) (58)
- Clarifying Confusion: The Confusion Assessment Method (2020) (50)
- Striatal dopamine transporter availability with [123I]β-CIT SPECT is unrelated to gender or menstrual cycle (2005) (50)
- [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia (1999) (46)
- Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease (2000) (43)
- Striatal dopamine transporters correlate with simple reaction time in elderly subjects (2008) (40)
- Apolipoprotein E ɛ4 Allele Increases Risk for Psychotic Symptoms in Alzheimer's Disease (2007) (35)
- Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET (2009) (28)
- SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine (1994) (25)
- Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease (2013) (24)
- Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease (2018) (20)
- Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (20)
- Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial (2018) (14)
- Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis (2021) (9)
- Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer’s disease (2021) (7)
- MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS (2017) (7)
- Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. (2004) (6)
- Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET (2021) (5)
- Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab (2020) (4)
- Neuroimaging in alzheimer’s disease: Relevance for treatment (2001) (4)
- Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD (2020) (4)
- Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis (2021) (4)
- "Estrogen replacement therapy for treatment of mild to moderate disease: A randomized controlled trial": Errata. (2000) (4)
- Resveratrol is safe and well-tolerated in individuals with mild-moderate dementia due to Alzheimer’s disease. (S33.009) (2015) (3)
- Synthesizing Multi-Tracer PET Images for Alzheimer's Disease Patients using a 3D Unified Anatomy-aware Cyclic Adversarial Network (2021) (3)
- TAU PET IN A4: PRELIMINARY REPORT (2018) (3)
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association (2020) (3)
- Clinical Correlates of Amyloid-Related Imaging Abnormalities (ARIA) in Phase 3 Studies of Bapineuzumab in Alzheimer's Disease (AD) (S44.002) (2013) (3)
- Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug Users (1992) (2)
- Pleiotropic effects of telomere length loci with brain morphology, and brain tissue expression. (2021) (2)
- Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease (2015) (2)
- Extended-Release Physostigmine in Alzheimer Disease (2016) (2)
- Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J (2021) (2)
- Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials? (2018) (2)
- Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PET (2017) (2)
- REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE (2019) (1)
- PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER’S DISEASE (2018) (1)
- Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment (2009) (1)
- P2-393 Alzheimer's disease patient and caregiver attitudes about proxy informed consent (2004) (1)
- Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer DiseaseA Randomized Controlled Trial (2000) (1)
- PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER’S DISEASE (2018) (1)
- Imaging Microglial Activation in Alzheimer's Disease: What Does It Mean? (2008) (0)
- Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states (2018) (0)
- A TARGETED MASS-SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER’S DISEASE (2018) (0)
- Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimerâ•Žs disease: Neuroimaging / multiâ•’modal comparisons (2020) (0)
- Gantnerumab In-depth Outcomes (2020) (0)
- A OF A NOVEL F-LABELED PET TRACER FOR IMAGING ASTROGLIOSIS (2019) (0)
- Neuroimaging in Alzheimer's Disease: Relevance for the Development of Therapeutic Agents (2006) (0)
- SympoSia S 1-APECS TRIAL OF THE BACE 1 INHIBITOR VERUBECESTAT FOR PRODROMAL ALZHEIMER ’ S DISEASE (2018) (0)
- PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER’S DISEASE: INITIAL EXPERIENCE (2018) (0)
- The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
- Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-J (2021) (0)
- Age-Related Brain Structure Differences, by Age of Onset, in Older Adults with Bipolar Disorder (2021) (0)
- PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER’S DISEASE: INITIAL EXPERIENCE (2018) (0)
- P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s Disease (2022) (0)
- DESIGN OF A PHASE-3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD (2018) (0)
- THE AGING RHESUS MONKEY IS AN APPROPRIATE NEW ANIMAL MODEL FOR STUDYING THE ETIOLOGY AND TREATMENT OF TAU PATHOLOGY IN ASSOCIATION CORTEX (2018) (0)
- LOSS OF PDE4D REGULATION OF CAMP-PKA-CALCIUM SIGNALING IN THE AGING ASSOCIATION CORTEX: INCREASING RISK FOR LOAD (2019) (0)
- Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease (2015) (0)
- Title Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease : A randomized controlled trial Permalink (2000) (0)
- ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY (2020) (0)
- Confusion Assessment Method (CAM) 1990 (2004) (0)
- Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease (2021) (0)
- COGNITIVE IMPAIRMENT ANTIDEMENTIA DRUGS IN A GERIATRIC CLINIC OF A PHASE-3 TRIAL (APECS) TO EVALUATE THE PRODROMAL AD (0)
- Title Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer ’ s disease (2000) (0)
- Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (0)
- progression in a randomized trial Growth hormone secretagogue MK-677 : No clinical effect on AD (2008) (0)
- Apolipoprotein E ε4 allele is associated with atrophy of the amygdala in Alzheimer's disease (2000) (0)
- ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER’S DISEASE: PRELIMINARY EXPERIENCE (2019) (0)
- ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASE (2019) (0)
- Operational criteria for patient recruitment in trials of mild cognitive impairment (2005) (0)
This paper list is powered by the following services:
Other Resources About Christopher H. van Dyck
What Schools Are Affiliated With Christopher H. van Dyck?
Christopher H. van Dyck is affiliated with the following schools:
